Registered title, quoted from ClinicalTrials.gov
A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04)
An open trial on breast cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07729956, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 75 years; sex: women only
Registered eligibility fields
Pathologically confirmed recurrent or metastatic triple-negative breast cancer;
Inclusion criterion 5
Toxicities from prior anti-tumor therapy must have recovered to ≤ Grade 1 as defined by NCI-CTCAE v6.0;
Inclusion criterion 10
Received surgery, radical radiotherapy, or immunotherapy within 4 weeks before the first dose;
Exclusion criterion 1
Prior treatment with other T-cell receptor-targeting agents (excluding PD-1/PD-L1);
Exclusion criterion 3
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
Inclusion criterion 4
Must have at least one measurable lesion as defined by RECIST v1.1;
Inclusion criterion 9
Active malignancy diagnosed within 3 years before randomization;
Exclusion criterion 10
HIV antibody positive, active HBV, or active HCV;
Exclusion criterion 23
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07729956, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Voluntarily sign the informed consent form and agree to comply with the protocol requirements;
- Female patients aged 18 to 75 years;
- Expected survival time ≥ 3 months;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
- Pathologically confirmed recurrent or metastatic triple-negative breast cancer;
- Confirmed PD-L1 expression positivity by central laboratory testing;
- No prior systemic anti-tumor therapy in the advanced/recurrent or metastatic setting;
- Agree to provide archived tumor tissue specimens (surgical specimens) or fresh tissue samples from primary or metastatic lesions obtained within 3 years;
- Must have at least one measurable lesion as defined by RECIST v1.1;
- Toxicities from prior anti-tumor therapy must have recovered to ≤ Grade 1 as defined by NCI-CTCAE v6.0;
- No severe cardiac dysfunction, with left ventricular ejection fraction (LVEF) ≥ 50%;
- Organ function levels must meet the protocol-specified requirements;
- Urine protein ≤ 1+ or < 1000 mg/24 h;
- For premenopausal women of childbearing potential, a pregnancy test (serum) must be performed within 7 days before starting treatment, and pregnancy must be ruled out; patients must not be lactating. All enrolled patients (regardless of sex) must use adequate barrier contraception throughout the entire treatment period and for 7 months after the end of treatment.
Exclusion Criteria:
- Received surgery, radical radiotherapy, or immunotherapy within 4 weeks before the first dose;
- Prior exposure to ADC drugs with topoisomerase I inhibitor payload;
- Prior treatment with other T-cell receptor-targeting agents (excluding PD-1/PD-L1);
- Use of immunomodulators within 14 days before the first study drug dose;
- History of severe cardiac or cerebrovascular disease;
- Receiving chronic systemic corticosteroids at >10 mg/day prednisone before the first dose;
- Active autoimmune or inflammatory disease;
- Any thrombotic event within 6 months before randomization;
- Prolonged QTc, complete left bundle branch block, or similar;
- Active malignancy diagnosed within 3 years before randomization;
- Hypertension uncontrolled by two antihypertensives;
- Poorly controlled diabetes/hyperglycemia;
- History of steroid-treated ILD/interstitial pneumonitis;
- Concurrent lung disease causing clinically significant respiratory impairment;
- Active CNS metastases;
- Severe infection within 4 weeks before randomization;
- Massive or symptomatic serosal effusion;
- Severe non-healing wound, ulcer, or fracture within 4 weeks before consent;
- Clinically significant bleeding or bleeding tendency within 4 weeks before consent;
- Inflammatory bowel disease, extensive bowel resection, immune enteritis, bowel obstruction, or chronic diarrhea;
- Allergy or contraindication to the study drug;
- History of autologous/allogeneic stem cell transplantation;
- HIV antibody positive, active HBV, or active HCV;
- History of severe neurological or psychiatric illness;
- Received or planning to receive live vaccine within 28 days before randomization;
- Other conditions rendering the patient unsuitable per investigator's judgment.
Quoted from ClinicalTrials.gov, NCT07729956, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07729956, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.